Susquehanna International Group, LLP Dbv Technologies S.A. Call Options Transaction History

Susquehanna International Group, LLP

15 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 15, 2022	BUY	$1.15 - $3.25 $12,879 - $36,400	11,200 New	11,200 $29,000
Q3 2021 Nov 15, 2021	SELL	$4.71 - $5.92 $143,184 - $179,968	-30,400 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$5.32 - $6.53 $12,236 - $15,019	-2,300 Reduced 7.03%	30,400 $166,000
Q1 2021 May 17, 2021	SELL	$2.75 - $6.57 $39,600 - $94,608	-14,400 Reduced 30.57%	32,700 $174,000
Q1 2020 May 15, 2020	SELL	$2.33 - $12.98 $6,058 - $33,748	-2,600 Reduced 5.23%	47,100 $185,000
Q4 2019 Feb 14, 2020	SELL	$6.75 - $11.15 $176,850 - $292,130	-26,200 Reduced 34.52%	49,700 $532,000
Q3 2019 Nov 14, 2019	BUY	$8.57 - $10.72 $205,680 - $257,280	24,000 Added 46.24%	75,900 $653,000
Q2 2019 Aug 14, 2019	BUY	$7.58 - $10.0 $15,918 - $21,000	2,100 Added 4.22%	51,900 $427,000
Q1 2019 May 15, 2019	BUY	$5.81 - $9.37 $7,552 - $12,180	1,300 Added 2.68%	49,800 $384,000
Q4 2018 Feb 14, 2019	BUY	$5.75 - $21.85 $159,850 - $607,430	27,800 Added 134.3%	48,500 $311,000
Q3 2018 Nov 14, 2018	SELL	$16.81 - $24.58 $285,770 - $417,860	-17,000 Reduced 45.09%	20,700 $465,000
Q2 2018 Aug 14, 2018	SELL	$18.6 - $24.94 $55,800 - $74,820	-3,000 Reduced 7.37%	37,700 $727,000
Q1 2018 May 15, 2018	SELL	$20.86 - $26.6 $986,678 - $1.26 Million	-47,300 Reduced 53.75%	40,700 $939,000
Q4 2017 Feb 14, 2018	SELL	$20.9 - $49.36 $6.13 Million - $14.5 Million	-293,300 Reduced 76.92%	88,000 $2.17 Million
Q3 2017 Nov 14, 2017	BUY	$39.62 - $46.17 $15.1 Million - $17.6 Million	381,300	381,300 $16.2 Million

3.2K

Ticker DBVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,776,992
Market Cap $845M
Description
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.